Elucid

Elucid is a Boston-based medical technology company dedicated to developing technology designed to help physicians better understand the root cause of cardiovascular disease. Elucid's PlaqueIQ software is the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of coronary plaques. The company is also pursuing an indication for FFRCT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. Elucid's mission is to improve patient care and make a positive impact in the field of cardiovascular disease management.

Elucid has garnered significant funding, most recently raising $80 million in Series C funding to support its commercialization and expansion plans. They have also moved into a new headquarters in Boston's Back Bay neighborhood to accommodate their growing team. Elucid's software is available for commercial use in the U.S., UK, EU, and South Korea and the company is continuing to expand its reach globally.

Elucid offers a hybrid work model, allowing employees to work from home and in the company's Boston headquarters. The new headquarters was designed to support a hybrid workforce and encourage collaboration, providing a variety of spaces for team members to work and socialize. The company also has a gym, locker room, and bike storage on-site to promote employee wellness.

Elucid offers a comprehensive benefits package that prioritizes employee wellness and a collaborative work environment. Their new headquarters features a gym area, locker room, and bike storage to encourage fitness. They also emphasize a hybrid work environment that allows for flexibility, while providing a modern space that fosters stronger team connections and enhances collaborative efforts. Further details about specific benefits like health insurance or retirement plans are not provided in the website content.

Elucid is a Boston-based AI medical technology company dedicated to developing technology that helps physicians better understand the root cause of cardiovascular disease. The company's mission is to provide comprehensive and accurate clinical insights based on ground-truth histology, enabling unprecedented precision healthcare for vascular disease. Their flagship software, PlaqueIQ, is the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology. This provides physicians with critical information for assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke.

Elucid fosters a collaborative and innovative culture, prioritizing team connections and employee wellness. The company has a hybrid workforce model, and its new headquarters features various spaces for collaborative work, social gatherings, and fitness activities like a gym area, locker room, and bike storage.